

Topical or oral ibuprofen for chronic knee pain in older people. The TOIB study

M Underwood,^{1*} D Ashby,² D Carnes,¹
E Castelnuovo,¹ P Cross,¹ G Harding,¹
E Hennessy,² L Letley,³ J Martin,³ S Mt-Isa,²
S Parsons,¹ A Spencer,⁴ M Vickers³ and K Whyte¹

¹ Centre for Health Sciences, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK

² The Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK

³ Medical Research Council, General Practice Research Framework, London, UK

⁴ Department of Economics, Queen Mary University of London, UK

* Corresponding author

Declared competing interests of authors: M Underwood has received speaker fees from Pfizer (the manufacturers of celecoxib and valdecoxib)

Published May 2008

This report should be referenced as follows:

Underwood M, Ashby D, Carnes D, Castelnuovo E, Cross P, Harding G, et al. Topical or oral ibuprofen for chronic knee pain in older people. The TOIB study. *Health Technol Assess* 2008;12(22).

Health Technology Assessment is indexed and abstracted in *Index Medicus/MEDLINE*, *Excerpta Medica/EMBASE* and *Science Citation Index Expanded (SciSearch®)* and *Current Contents®/Clinical Medicine*.



Contents

List of abbreviations	vii	Methods	75
Executive summary	ix	Results	79
1 Introduction	1	6 Qualitative study exploring patients' beliefs about knee pain and topical or oral ibuprofen treatment	97
Knee pain and knee osteoarthritis in older people	1	Introduction	97
Drug treatment of knee pain in older people	1	Method	97
Effectiveness and safety of oral NSAIDs	2	Results	99
Effectiveness and safety of topical NSAIDs	3	Discussion	103
Oral versus topical NSAID effectiveness	4	Conclusions	106
Role of patient preferences	4	7 Discussion	107
Health economics of oral and topical NSAIDs	5	Key findings	107
Patient preference for oral or topical NSAIDs	5	Qualitative study	110
Which NSAID?	5	Strengths and potential weaknesses of the study	111
2 Aims, objectives and overview of the study	7	Conclusions	114
Aims	7	Acknowledgements	115
Objectives	7	References	117
Overview	7	Appendix 1 Delphi study questionnaire	125
3 Defining minor clinical adverse effects	9	Appendix 2 GPRF quality control documentation	133
Background	9	Appendix 3 Health economic evaluation (unit costs used in the cost-effectiveness analysis)	141
Method	9	Appendix 4 Qualitative study data	149
Results	11	Health Technology Assessment reports published to date	157
Discussion	12	Health Technology Assessment Programme	173
Conclusion	15		
4 The randomised controlled trial and the patient preference study	17		
Introduction	17		
Method	18		
Results	31		
5 Economic evaluation of oral and topical ibuprofen	75		
Introduction	75		